ライフサイエンスコーパス: autologous transplant

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 unger patients by high-dose melphalan and an autologous transplant.

2 -matched transplant, and one had received an autologous transplant.

3 ollowed by HLA-matched related allogeneic or autologous transplant.

4 autologous, and 597 (67%) received unpurged autologous transplants.

5 ymphomas, including some that relapsed after autologous transplants.

6 Seventeen patients had previous autologous transplant; 6 were in complete remission, and

7 f 48 such patients: mean age 47.7 years, 52% autologous transplant and 67% peripheral stem cell sourc

8 ons for allogeneic transplantation vis-a-vis autologous transplant and to discuss the rationale and p

9 fractory to both; (31 [70%]) had received an autologous transplant, and (30 [62%]) had high-risk cyto

10 reviously reported, and that early onset and autologous transplant are favorable prognostic indicator

11 tic alternative for patients relapsing after autologous transplant, but induction of a remission is t

12 sone, cytarabine, and cisplatin (DHAP), with autologous transplant consolidation for those with chemo

13 In humans, autologous transplants derived from bone marrow (BM) usu

14 Our previous work in patients undergoing autologous transplant for multiple myeloma (MM) or breas

15 was intubated, had an allogeneic rather than autologous transplant, had an infection or gastrointesti

16 e assessed the role of thymic function after autologous transplant in adults, correlating serial comp

17 e is growing evidence for the role of tandem autologous transplant in breaking refractory disease.

18 Supporting the potential for autologous transplants in Hirschsprung disease, we obser

19 39 +/- 6 mm(3); n = 13), similar to those of autologous transplanted iNOS(+/+) mice (39 +/- 4 mm(3);

20 2 mm(3); n = 13; mean +/- SE) compared with autologous transplanted iNOS(-/-) mice (24 +/- 3 mm(3);

21 A review of the data on tandem vs sequential autologous transplants is provided.

22 Because gene therapy represents an autologous transplant, it obviates immune suppression be

23 Although autologous transplants may prolong survival, most patien

24 o studies of vitrified vessel segments in an autologous transplant model showed no adverse effects of

25 For patients relapsing after autologous transplant, more recent analyses have reporte

26 on and remodeling, suggesting the utility of autologous transplant of bone marrow-derived mononuclear

27 of predicted (P = .0002), allogeneic versus autologous transplant (P = .0003), diffusion capacity of

28 ation relating to 19412 allogeneic and 17950 autologous transplant patients.

29 l death were associated with higher costs in autologous transplant recipients ($18,400 and $20,500, r

30 However, allogeneic and autologous transplant recipients each had distinctive ri

31 tment category and was most pronounced among autologous transplant recipients.

32 opoietic recovery in both the allogeneic and autologous transplant settings.

33 py" approaches with stem cell or bone marrow autologous transplants still have not found a role in th

34 After autologous transplant, the donor genotype from lentiviru

35 Three autologous transplants were performed with CD34+ cell fr

36 ) were assessed in 10 patients who underwent autologous transplants with stem cells, cryopreserved in

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。